Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | NPY4R | P50391 | 2/20 | 0.43 |
| ▸ | ACE | P12821 | 2/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16507850 | 0.95 | NPY4R (0.47) | NPY4RACEREN | |
| SCHEMBL16507827 | 0.92 | ACE (0.49) | PTPN1NPY4RACEREN | |
| SCHEMBL16358940 | 0.89 | ACE (0.38) | ACE | |
| SCHEMBL16507942 | 0.86 | ACE (0.39) | NPY4RACE | |
| SCHEMBL31020877 | 0.85 | ACE (0.47) | NPY4RACE | |
| SCHEMBL13363654 | 0.83 | ACE (0.49) | NPY4RACEREN | |
| SCHEMBL16508075 | 0.83 | NPY4R (0.53) | NPY4R | |
| SCHEMBL16508123 | 0.81 | REN (0.38) | REN | |
| SCHEMBL29790444 | 0.81 | NPY4R (0.48) | NPY4R | |
| SCHEMBL12045120 | 0.81 | REN (0.41) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | ANTHOR THERAPEUTICS, INC. | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | PTH1R, MC1R, CASR | PTPN1 826/4885NPY4R 1387/4885ACE 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.